BUY Aurobindo Pharma — Prakash Gaba, 08 Sept 2026

byPrakash GabaHorizon: Swing (≤2wk)8 Sept 2026via CNBC Awaaz.

Entry₹1,678.6Inferred

Target₹1,700

Stop loss₹1,670-0.51% risk

Exit₹1,670Stop-loss hit — time not yet verified

Stop-loss hit-0.51%

Follow Prakash Gaba for new calls(29% target hit, 196 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 2 active Swing calls on AUROPHARMA See 268 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 10 Sept, 12:20 pm IST

6 supporting5 neutral2 opposing

Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·10 Sept · today

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·8 Sept · yesterday

Aurobindo stock gains on generic Advair launch

NewsGoogle News·1 Sept · 1w ago

Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD

NewsEt-Markets·31 Aug · 1w ago

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.

NSE · Press Release·31 Aug · 1w ago

Neutral / worth noting (5)

Upcoming Stock Split, Dividend, Bonus Issue THIS Week: Aurobindo Pharma, Muthoot Finance, More | Full List

NewsGoogle News·5 Sept · 4d ago

Aurobindo Pharma moves up as its arm incorporates wholly owned subsidiary

NewsGoogle News·2 Sept · 1w ago

Aurobindo Pharma arm Apitoria incorporates Avogent Lifesciences as subsidiary

NewsGoogle News·1 Sept · 1w ago

Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.

BSE · Company Update·1 Sept · 1w ago

Aurobindo Pharma’s API plant gets three US FDA observations after inspection

NewsCnbc-Tv18·28 Aug · 2w ago

Weighs against the BUY call (2)

USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra

NewsNdtv-Profit·28 Aug · 2w ago

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.